Private equity firm Limerston Capital has completed the acquisition of Gosport-based laboratory Wickham Micro and appointed industry veteran Mark Hammond as its CEO.
Private equity firm Limerston Capital has completed the acquisition of Gosport-based laboratory Wickham Micro and appointed industry veteran Mark Hammond as its CEO.
The acquisition of the laboratory is part of a wider growth plan, of which Hammond will play a pivotal part.
Wickham Micro is an established laboratory and has provided expert microbiology and in-vitro toxicology services to the pharmaceutical and medical device sectors for almost 60 years. The team works with global brands to deliver comprehensive testing services, enabling them to launch and release their products safely and efficiently, facilitating safe access to critical medicines and devices that are needed across the world.
As part of the acquisition, a separate entity for the (in-vivo) toxicity testing part of the business has been created and will remain under the control of the previous owners as will the real estate.
Hammond joins from PBD Biotech and has held senior roles within both private and public companies, including Melbourn Scientific, Intertek and Aesica Pharmaceuticals.
